Obesity is a health abnormality that increases the risk and incidence of developing atherosclerosis primarily in populations of developed countries including United States. Studies emphasize that obesity has a strong association with cardiovascular diseases (CVD). Visceral obesity is obesity due to increased deposition of fat in the abdominal viscera and is the initial stage for CVD. Chronic inflammation of the adipose tissue leads to release of cytokines and inflammatory factors that play a key role in promoting CVD. Tumor necrosis factor α (TNF-α) is a cytokine produced by adipose tissue, endothelial cells and macrophages that play a major role in inflammatory response and monocyte recruitment to early lesions of atherosclerosis. TNF-α is known to be a potent activator of nuclear factor kappa B (NF-κB), a family of transcription factors involved in the atherosclerotic process. NF-κB regulates adhesion molecules like ICAM and VCAM and chemokines such as monocyte chemo-attractant protein (MCP-1) and IL-8 that contribute towards CVD. Another well characterized marker of cardiovascular risk is C-reactive protein (CRP). CRP activates NF-κB activity that further regulates the expression of MCP-1 and VCAM. Insulin resistance induced by high glucose and atherosclerosis are tightly intertwined disorders. Hyperglycemia induces damage to the endothelium through activation of NF-κB pathway amongst others. Insulin-like Growth Factor Binding Protein-3 (IGFBP-3), a major binding protein of IGF modulates IGF by regulating IGF binding to its receptors. It also contributes to the pathophysiology of a variety of disease states in an IGF independent manner. With respect to IGF-I/IGF-I receptor independent actions of IGFBP-3, it is known to interfere and inhibit the NF-κB pathway. Since NF-κB plays a significant role in the progression of atherosclerosis, we explored the role of IGFBP-3 as a therapeutic target in cardiovascular diseases. In our experiments using human aortic endothelial cells (HAEC), we demonstrated that IGFBP-3 inhibits the elevated NF-κB activity induced by treatment with factors involved in CVD such as TNF-α, CRP and high glucose. This subsequently led to the inhibition of NF-κB regulated proteins such as ICAM, VCAM and MCP-1 at mRNA and protein levels. Taken together, our findings strongly suggest that IGFBP-3 may prevent/inhibit the initiation/progression of CVD and pose as an ideal therapeutic candidate for obesity induced CVD. Nothing to Disclose: LM, YO